Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04040491
Other study ID # hnslblzlzx20190702
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 1, 2019
Est. completion date September 1, 2021

Study information

Verified date May 2020
Source Zhengzhou University
Contact Mingzhi D Zhang
Phone +8613838565629
Email Mingzhi_zhang@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma.


Description:

Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional CHOP regimen. The investigators have been proceeding this trial to evaluate the efficacy and safety of the PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 1, 2021
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group 14 Years to 65 Years
Eligibility Inclusion Criteria:

- age:14-65 years;Eastern Cooperative Oncology Group (ECOG)score=3;expected survival=3 months

- patients with Peripheral T-cell Lymphoma diagnosed by immuno-histochemistry (IHC);

- acceptable hematological indicators, no chemotherapy contraindications;

- total bilirubin = 1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) = 2.5 x upper age limit (ULN), if the abnormal laboratory parameters are considered to be caused by lymphoma, patients Eligible conditions should be adjusted to be incorporated into the group;

- At least one measurable lesion by CT or PET-CT(Positron Emission Tomography-Computed Tomography);

- exclude other major diseases, normal heart and lung function;

- Female patients of childbearing age are negative for pregnancy test;

- Cooperate with follow-up;

- There are no other related treatments including traditional Chinese medicine, immunotherapy, and biologic therapy (except for the treatment of anti-bone metastases and other symptoms);

- Signing informed consent *: Pathological histology must be consulted by a pathologist at a provincial hospital.

Exclusion Criteria:

- Patients with ALK-positive Anaplastic Large Cell Lymphoma or angioimmunoblastic T-cell lymphoma

- rejecting providing blood preparation;

- allergic to drug in this study and with metabolic block;

- rejecting adopting reliable contraceptive method in pregnancy or lactation period;

- uncontrolled internal medicine disease(including uncontrolled diabetes,severe incompetence cardiac, lung, liver and pancreas);

- with severe infection;

- with primary or secondary central nervous system tumor invasion;

- with immunotherapy or radiotherapy contraindication;

- ever suffered with malignant tumor;

- having peripheral nervous system disorder or dysphrenia;

- with no legal capacity,medical or ethical reasons affecting research proceeding;

- participating other clinical trials simultaneously;

- adopting other anti-tumor medicine excluding this research;

- Patients with immunodeficiency, such as primary immunodeficiency syndrome or organ transplant recipients

- Human immunodeficiency virus (HIV)-positive patients

- the researchers considering it inappropriate to participate in the study.

- Patients with immune system diseases

Study Design


Intervention

Drug:
PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-a. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.

Locations

Country Name City State
China Oncology Department of The First Affilliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Mingzhi Zhang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate The proportion of patients whose tumor volume has reduced to a predetermined value and can maintain the minimum time limit is the sum of complete and partial mitigation. From date of randomization until the date tumor volume has reduced, assessed up to 36 months
Primary Progression-free Survival The time between the start of randomization and the progression of the tumor (any aspect) or (for any reason) death From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
Primary Overall Survival Time from randomization to death for any reason From date of randomization until date of death from any cause, assessed up to 36 months
See also
  Status Clinical Trial Phase
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Recruiting NCT02445404 - Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL Phase 2
Completed NCT02168140 - CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Phase 1
Terminated NCT01644253 - Phase 1b Safety and Efficacy Study of TRU-016 Phase 1
Completed NCT01689220 - A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea Phase 1
Completed NCT01435863 - A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) Phase 1
Completed NCT01427881 - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Phase 2
Terminated NCT00441025 - The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Active, not recruiting NCT04312841 - Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Phase 2
Terminated NCT01678443 - Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT02142530 - Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Phase 1
Completed NCT02264613 - ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Phase 1/Phase 2
Terminated NCT01408043 - Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma N/A
Completed NCT00131937 - Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Phase 2
Completed NCT00791947 - A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT Phase 2
Recruiting NCT04880746 - Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study Phase 3
Recruiting NCT03964480 - Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.